ATE349443T1 - N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen - Google Patents

N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen

Info

Publication number
ATE349443T1
ATE349443T1 AT02762582T AT02762582T ATE349443T1 AT E349443 T1 ATE349443 T1 AT E349443T1 AT 02762582 T AT02762582 T AT 02762582T AT 02762582 T AT02762582 T AT 02762582T AT E349443 T1 ATE349443 T1 AT E349443T1
Authority
AT
Austria
Prior art keywords
phenylamines
methylthiazole
pyrimidine
antiproliferative compounds
antiproliferative
Prior art date
Application number
AT02762582T
Other languages
English (en)
Inventor
Shudong Wang
Christopher Meades
Gavin Wood
Andrew Osnowski
Peter Martin Fischer
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0123377A external-priority patent/GB0123377D0/en
Priority claimed from GB0123629A external-priority patent/GB0123629D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE349443T1 publication Critical patent/ATE349443T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Refuge Islands, Traffic Blockers, Or Guard Fence (AREA)
AT02762582T 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen ATE349443T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0123377A GB0123377D0 (en) 2001-09-28 2001-09-28 Anticancer compounds
GB0123629A GB0123629D0 (en) 2001-10-02 2001-10-02 Anticancer compounds

Publications (1)

Publication Number Publication Date
ATE349443T1 true ATE349443T1 (de) 2007-01-15

Family

ID=26246590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762582T ATE349443T1 (de) 2001-09-28 2002-09-27 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen

Country Status (13)

Country Link
US (2) US7388015B2 (de)
EP (2) EP1430051B1 (de)
JP (1) JP4495963B2 (de)
CN (1) CN100500663C (de)
AT (1) ATE349443T1 (de)
BR (1) BR0212944A (de)
CA (1) CA2460909A1 (de)
CZ (1) CZ2004354A3 (de)
DE (1) DE60217140T2 (de)
IL (1) IL161092A0 (de)
MX (1) MXPA04002914A (de)
NZ (1) NZ531596A (de)
WO (1) WO2003029248A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
AU2004285745A1 (en) 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
WO2005040135A1 (ja) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CA2576159A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
BRPI0517253A (pt) * 2004-10-28 2008-10-07 Irm Llc compostos e composições como moduladores de trajetória de ouriço
CA2590939C (en) * 2004-12-17 2011-10-18 Amgen Inc. Aminopyrimidine compounds and methods of use
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CA2636077C (en) * 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
EP2100894A1 (de) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinone verwendbar als Plk1 (polo-like kinase) Hemmen
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CN101928258B (zh) * 2010-08-18 2014-10-29 杭州民生药业有限公司 1-(2-取代苯胺基-4-甲基-噻唑-5)-3-取代苯基-丙烯酮衍生物、制备方法及其制药用途
CN103058949A (zh) * 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
CN105267214B (zh) * 2014-07-21 2019-04-30 沈阳化工研究院有限公司 N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途

Also Published As

Publication number Publication date
US20060199830A1 (en) 2006-09-07
CN1617870A (zh) 2005-05-18
US7388015B2 (en) 2008-06-17
IL161092A0 (en) 2004-08-31
EP1760082A1 (de) 2007-03-07
CA2460909A1 (en) 2003-04-10
MXPA04002914A (es) 2005-06-20
JP2005508931A (ja) 2005-04-07
JP4495963B2 (ja) 2010-07-07
CN100500663C (zh) 2009-06-17
NZ531596A (en) 2005-08-26
EP1430051A1 (de) 2004-06-23
US20040259894A1 (en) 2004-12-23
WO2003029248A1 (en) 2003-04-10
US7427627B2 (en) 2008-09-23
EP1430051B1 (de) 2006-12-27
CZ2004354A3 (cs) 2004-06-16
DE60217140D1 (de) 2007-02-08
BR0212944A (pt) 2004-10-13
DE60217140T2 (de) 2007-04-19

Similar Documents

Publication Publication Date Title
ATE349443T1 (de) N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen
ATE373653T1 (de) Pyrimidine verbindungen
ATE365163T1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE520663T1 (de) Stickstoff atom enthaltenden heteroaryl- harnstoffe als inhibitoren der p38-kinase
ATE466581T1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
NL300357I2 (nl) Beta-amino tetrahydroimidazo (1,2-A)pyrazines en
NO20074964L (no) Pyrimidinderivater for behandling av hyperproliferative forstyrrelser
DK1347971T3 (da) Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
DK2201840T3 (da) Hæmmere af Brutons tyrosinkinase
DE60228103D1 (de) Chemische verbindungen
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE60228330D1 (de) Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
ATE434614T1 (de) 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
ATE279410T1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
MXPA05010975A (es) Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1430051

Country of ref document: EP